|
|
Blood, Vol. 111, Issue 3, 1603-1609, February 1, 2008
The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition
Blood Chng et al.
111: 1603
Supplemental materials for: Chng et al
Files in this Data Supplement:
- Table S1. The relevant biological and clinical information related to the newly-diagnosed MM patients in this dataset (PDF, 14.9 KB)
- Table S2. High and low CI according to molecular classification (PDF, 306 KB)
- Table S3. Differentially expressed genes between tumors with high or low (PDF, 97.7 KB)
- Table S4. Gene ontology categories enriched among genes differentially expressed between tumors with high or low CI (PDF, 864 KB)
- Figure S1. PI, t(4;14) and CKS1B are significant prognostic factors in UAMS dataset (JPG, 67.7 KB)
-
(A) Patients with t(4;14) have significantly shorter survival than patients without this genetic abnormality (median survival 47.4 months versus unknown, log-rank p = 0.002). (B) Patients with PI > 2 have significantly shorter survival than those with PI < 2 (median survival 39.8 months versus not yet reach, log-rank p < 0.0001). (C) Patients with normalized CKS1B mRNA expression greater than 1 have significantly shorter survival than those with lower CKS1B mRNA expression (median survival not yet reach versus not yet reach, log-rank p = 0.005).
- Figure S2. A high CI is associated with shorter survival regardless of response to bortezomib (JPG, 57.4 KB)
-
(A) Among patients who responded to bortezomib, those with high CI have a significantly shorter survival (median survival 13.1 months vs 24.1 months, log-rank p = 0.04). (B) Among patients who did not respond to bortezomib, those with high CI have a significantly shorter survival (median survival 6.1 months versus 15.1 months, log-rank p = 0.02).
- Figure S3. Impact of High-risk GEP index and high CI on survival (JPG, 58.1 KB)
-
Four groups of patients can be identified: Those with both high-risk GEP index and high CI, those with high CI only, those with high-risk GEP index only and those with neither. Overall, the survival curves are significantly different by log-rank test (p < 0.0001). However, on pair-wise analysis, the difference in survival of patients with high-risk GEP index and high CI, high CI only or high-risk GEP index only, 29.8 months, 42.7 months and 36.1 months respective, are not statistically significant.
- Figure S4. HMCLs with lower CI are resistant to Aurora Kinase Inhibitor (JPG, 77.2 KB)
-
(A) 12 HMCLs are treated with an aurora kinase inhibitor, MLN8054, across a range of concentration and growth inhibition was assessed by MTT assay. 3 of these HMCLs demonstrated relative resistance to aurora kinase inhibition. (B) When the CI of these HCMLs are compared, the 3 resistant HMCLs have lower CI, with 2 of them less than 4.
|
|
